期刊文献+

食管癌组织TopoⅡα和MGMT表达及其临床意义的研究 被引量:3

Expression and clinical significance of TopoⅡα and MGMT in esophageal carcinoma tissues
原文传递
导出
摘要 目的:探讨潮汕地区食管鳞癌组织中Ⅱ型拓扑异构酶α(TopoⅡα)和DNA修复酶MGMT的表达及其相关性和临床意义。方法:采用免疫组织化学染色方法(EnVision二步法)观察40例食管鳞癌组织、20例上切缘正常组织中TopoⅡα和MGMT的表达。结果:在正常食管黏膜上皮中TopoⅡα的阳性表达率为35%,MGMT的阳性表达率为100%;而在食管鳞癌组织中TopoⅡα的阳性表达率为80%,MGMT的阳性表达率为50%,差异均有统计学意义,P<0.001;在食管鳞癌组织中TopoⅡα、MG-MT的表达呈负相关,r=-0.976,P<0.001。结论:TopoⅡα和MGMT蛋白在食管鳞癌组织中的表达可以作为食管鳞癌早期诊断和预后判断的参考指标。 OBJECTIVE:To investigate the expression,correlation and clinical significance of TopoⅡα and MGMT in esophageal carcinoma of Chaoshan area.METHODS:Immunohistochemical method(EnVision) was used to investigate the expression of TopoⅡα and MGMT in 40 esophageal squamouscell carcinomas and 20 normal tissues of the top distance cutting edge,and analyzed its correlation and clinical significance.RESULTS:For TopoⅡα,35% expression was observed in normal esophageal tissues,but 80% expression in esophageal squamous cell carcinoma,P0.001.For MGMT,100%expression in normal tissue was observed,while 50% in esophageal squamous cell carcinoma,P0.001.The expression of TopoⅡα and MGMT in esophageal squamous cell carcinoma as a negatively correlation(r=-0.976,P0.001).CONCLUSION:The expression of TopoⅡα and MGMT can be used as early diagnosis and prognosis biomarkers in esophageal squamous cell carcinoma tissues.
出处 《中华肿瘤防治杂志》 CAS 2010年第22期1818-1820,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 食管肿瘤/病理学 TopoⅡα MGMT 免疫组织化学 esophageal neoplasms/pathology TopoⅡα MGMT immunohistochemistry
  • 相关文献

参考文献10

  • 1Mattila R, Alanen K, Syrjanen S. Immunohistochemical study on topoisomerasc Ⅱ alpha, Ki 67 and cytokeratin-19 in oral lichen planus lesions[J]. Arch Dermatol Res, 2007,298 (8): 381-388.
  • 2孙旸,李立安,宋磊,朱守兰.拓扑异构酶Ⅱα和Ki-67表达与子宫肉瘤预后的相关性研究[J].解放军医学杂志,2008,33(11):1325-1328. 被引量:6
  • 3Ishikawa T, Zhang S S, Qin X, et al. DNA repair an cancer: lessons from mutant mouse models[J]. Cancer Sci, 2004,95 (2) : 112-117.
  • 4John R G, Andrei V O, Hiroshi H, et al. Acridine-based agents with topoisomerase Ⅱ activity inhibit pancreatic cancer cell proliferation and induce apoptosis [J]. J Med Chem, 2008, 51 (2) : 179-182.
  • 5Edurne A, Socorro M P, Maryou B K, et al. Topoisomerase Ⅱ alpha amplification may predict benefit from adjuvant anthrecyclines in HER2 positive early breast cancer[J]. Breast Cancer Res Treat, 2007,106(2) :181-189.
  • 6Ferrandina G, Petrillo M, Carbone A, et al. Prognostic role of topoisomerase Iia in advanced ovarian cancer patients[J]. Br J Cancer, 2008, 98(12): 1910-1915.
  • 7唐郡,阎晓初,彭贵勇,孙永刚,程龙,陈春燕.食管鳞状细胞癌P-gp、GST-π、TopoⅡ的表达及临床意义[J].第三军医大学学报,2007,29(17):1692-1695. 被引量:9
  • 8Baumann S, Keller G, Puhringer F, et al. The prognostic impact of O6-Methylguanine DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma [J]. Int Cancer, 2006,119(2): 264-268,.
  • 9Fang M Z, Jin Z, Wang Y, et al. Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines[J]. Int J Oncol,2005,26(3) :615-622.
  • 10Guo M, Ren J, House M G, et al. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus[J]. Clin Cancer Res,2006,12(15):4515-4522.

二级参考文献20

  • 1周英琼,曾思恩,侯巧燕,陆明深,张美艳.P-gp、GST-Л、p53和CD44v6在肺癌中的表达[J].肿瘤防治研究,2005,32(11):699-701. 被引量:2
  • 2赵韬,魏莉,刘健.胃癌多药耐药的研究进展[J].实用临床医药杂志,2005,9(11):42-44. 被引量:3
  • 3Mattila R, Alanen K, Syrjanen Immunohistochemical study on to-poisomerase II alpha, Ki-67 and cytokeratin-19 in orallichen planus lesions. Arch Dermatol Res, 2007, 298(8) :381.
  • 4Kruse A J, Gudlaugsson E, Helliesen T, et al. Evaluation of prospective, routine application of Ki-67 immunoquantitation in early (;IN for assessment of short-term progression risk. Anal Quant Cytol Histol, 2004, 26(3) : 134.
  • 5Munstedt K, von Georgi R, Franke FE. Correlation between MIB-1 determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas. Cancer Invest, 2004, 22(2):185.
  • 6Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gyne col Oncol, 2004, 92(1):175.
  • 7Akhan SE, Yavuz E, Tecer A, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leio- myosarcomas: A clinicopathologic study. Gynecol Oncol, 2005, 99 (1):36.
  • 8Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of un-certain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Aeta Obstet Gynecol Scand, 2004, 83(11) : 1085.
  • 9Davies L, Hardin NJ, Beatty BG. Can Ki-67 predict recurrence of NO squamous cell carcinoma of the tongue? Ann Otol Rhinol Laryngol, 2006, 115(1):12.
  • 10Jalava P, Kuopio T, Juntti-Patinen L, et al. Ki67 immunohisto-chemistry: a valuable marker in prognostication but with a risk of misclassifieation: proliferation subgroups formed based on Ki67 immunoreaetivity and standardized mitotic index. Histopathology, 2006, 48(6) :674.

共引文献13

同被引文献59

  • 1潘娟新,徐炜.多药耐药基因在涎腺粘液表皮样癌中的表达及意义[J].实用肿瘤学杂志,2006,20(1):12-13. 被引量:4
  • 2Baguley BC. Multidrug resistance in cancer[J].Methods in Molecular Biology,2010.1-14.
  • 3Rees DC,Johnson E,Lewinson O. ABC transporters:the power to change[J].Nature Reviews Molecular Cell Biology,2009,(03):218-227.
  • 4Li Y,Yuan H,Yang K. The structure and function of Pglycoprootein[J].Current Medicinal Chemistry,2010,(08):786-800.
  • 5Loo TW,Bartlett MC,Clark DM. Nucleotide binding,ATP hydrolysis and mutation of the catalytic carboxvlates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments[J].Biochemistry,2007,(32):9328-9336.
  • 6Ricardo P. Multidrug resistance and propects in anticancer drug treament[J].Current Medicinal Chemistry,2006,(16):1859-1876.
  • 7Marignol L,Coffey M,Lawler M. Hypoxia in prostate cancer:A powerful shield again tumor destruction[J].Cancer Treatment Reviews,2008,(04):313-327.
  • 8Frova C. Glutathione transferases in the genoniesera:new insights and perpective[J].Biomolecular Engineering,2006,(04):149-169.
  • 9Medeiros R,Pereira D,Afonso N. Platinum paclitaxel 3/based chemotherapy in advanced ovarian carcinama:glutathione-S-transferase genetic polymorphisms as predictive biomarkers of disease outcome[J].International Journal of Clinical Oncology,2003.156-161.
  • 10Kantidze OL,larovaia OV,Razin SV. Assembly of nuclearmatrix-bound protein complexes involved in non-homologous end joining is induced by inhibition of DNA topoisomerase Ⅱ[J].Journal of Cell Physiology,2006,(03):660-667.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部